Diadema Partners LP Takes $2.47 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Diadema Partners LP bought a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 165,965 shares of the company's stock, valued at approximately $2,471,000. Arcus Biosciences comprises 1.0% of Diadema Partners LP's investment portfolio, making the stock its 20th biggest position. Diadema Partners LP owned 0.18% of Arcus Biosciences as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Gilead Sciences Inc. bought a new position in Arcus Biosciences during the fourth quarter valued at approximately $447,610,000. Trexquant Investment LP lifted its holdings in shares of Arcus Biosciences by 241.5% in the 4th quarter. Trexquant Investment LP now owns 300,548 shares of the company's stock worth $4,475,000 after acquiring an additional 212,552 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Arcus Biosciences by 11.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock valued at $25,348,000 after purchasing an additional 178,351 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Arcus Biosciences during the 4th quarter valued at $954,000. Finally, ExodusPoint Capital Management LP purchased a new position in Arcus Biosciences in the 4th quarter worth $896,000. Institutional investors own 92.89% of the company's stock.

Wall Street Analysts Forecast Growth

RCUS has been the subject of several analyst reports. HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. Morgan Stanley lowered their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Barclays dropped their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday. Finally, Bank of America lowered their target price on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of "Buy" and an average price target of $28.38.

Arcus Biosciences Stock Performance

NYSE RCUS traded down $0.11 during trading hours on Friday, hitting $8.30. 503,744 shares of the company's stock traded hands, compared to its average volume of 800,497. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $18.98. The firm has a market capitalization of $872.65 million, a P/E ratio of -2.63 and a beta of 1.54. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The business's fifty day moving average price is $8.79 and its two-hundred day moving average price is $13.07.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.17) by $0.14. The firm had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Insider Activity

In other news, CEO Terry J. Rosen bought 19,800 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $10.18 per share, with a total value of $201,564.00. Following the acquisition, the chief executive officer now owns 2,554,160 shares of the company's stock, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Yasunori Kaneko purchased 20,000 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were acquired at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the acquisition, the director now owns 28,400 shares of the company's stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.